Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24088494 | 0.82 | PIK3CD (0.39) | ALDH1A1LMNANPC1 | |
| SCHEMBL21995965 | 0.80 | UGCG (0.38) | PLATALDH1A1LMNASMN1; SMN2NPC1 | |
| SCHEMBL21752525 | 0.77 | LMNA (0.45) | ALDH1A1LMNASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL30352828 | 0.76 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL21752707 | 0.73 | ALDH1A1 (0.36) | ALDH1A1LMNASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL21752706 | 0.73 | ALDH1A1 (0.36) | ALDH1A1LMNASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL23780221 | 0.73 | ALDH1A1 (0.36) | ALDH1A1LMNASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL21752501 | 0.73 | KMT2A (0.40) | ALDH1A1SMN1; SMN2NPC1CYP1A2HPGD | |
| SCHEMBL31011271 | 0.72 | STAT3 (0.41) | ALDH1A1LMNASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL21752599 | 0.72 | STAT3 (0.41) | ALDH1A1LMNASMN1; SMN2NPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, AADAC | PLAT 4282/4885ALDH1A1 155/4885LMNA 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.